👁️

Ophthalmology

Eye disease treatments including gene therapies for inherited retinal diseases, anti-VEGF agents, and glaucoma therapies.

Companies

Pipeline Drugs

1163

Key People

1290

Ophthalmology Pipeline (1163 drugs)

Commercial: 168Pre-clinical: 134Preclinical: 97Approved: 78Phase 2: 77Phase 3: 71Phase 1: 41Development: 36Marketed: 28Phase 1/2: 26Discovery: 22Research: 20Phase III: 14Phase 2/3: 13Unknown: 12Phase 2b: 11Phase I/II: 10Market: 7Not Disclosed: 6Clinical Development: 6Phase 2a: 6Pre-clinical/Development: 6Early Phase: 6Launched: 5Phase II: 5Pre-clinical / Clinical: 5Research/Pre-clinical: 5Research/Development: 5Development/Validation: 5Preclinical/Research: 5Not Applicable (Service Provider): 5ANDA Pending: 5Phase I: 4NDA Submitted: 4Clinical Trials: 4Pre‑clinical: 4Under Development: 3Clinical: 3Pivotal Trial: 3Approved/Commercial: 3Investigational: 3Research/Preclinical Tools: 3Phase 1/2a: 3Clinical-stage: 3Commercial Launch: 3Development/Accreditation: 3Discovery/Preclinical: 3Research/Pre‑clinical: 3ANDA Approved: 3Phase 1b: 2Regulatory Review: 2BLA Submitted: 2Approved (Tentative): 2Research & Development: 2Phase 1b/2a: 2Pre-Clinical: 2Preclinical/Clinical: 2Preclinical/Discovery: 2Research/Service: 2Pre-clinical/Early Clinical: 2Pivotal: 2Design & Prototype: 2Research/Exploration: 2Phase 4: 2Pre-clinical/Feasibility: 2Early Clinical: 2Preclinical/Technical Development: 2Exploratory Biomarker in Clinical Studies: 2Service: 2Feasibility: 2Proof-of-Concept: 2Not Specified: 2Development/Pre-commercial: 2Commercial/Development: 2preclinical: 2Pre‑clinical/early clinical: 2Launched (2026): 2Launched (2025): 2Not specified: 2CE marked, commercial: 2Regulatory Approved: 2IND Planned: 2Phase 3 Ready: 1Phase Ib/IIa: 1Phase Ib/II: 1FDA 510(k) cleared: 1CE Marked: 1Development/Regulatory: 1Commercial Partnership: 1Research/Discovery: 1Approved (Japan): 1Pre-Market: 1Pre-clinical/Clinical: 1Various: 1Commercial (Limited): 1Early Feasibility Study: 1Clinical Stage: 1Prototype: 1Pre-clinical/R&D: 1Strategic Development: 1Early Clinical Investigation: 1Pivotal Trial (US) / Post-Market (EU): 1Research/Preclinical: 1Commercial (Ongoing Development): 1ANDA Filed/Pre-approval: 1Phase 1/2 (inferred): 1Regulatory: 1N/A (Service): 1N/A (Commercial): 1Investigational / CE Mark: 1Service Offering: 1Clinical Trial & Product Eng.: 1Pivotal Trial Planned: 1Phase 1b/2: 1Pilot Clinical Study Completed: 1Discovery/IND-Enabling: 1Development/Commercial Expansion: 1Clinical Validation/Service Launch: 1Phase 2/3 (assumed post-ODD): 1Hit to Lead: 1Platform Development: 1Phase 2b/3: 1Pre-clinical/Phase 1: 1Preclinical or Phase 1: 1Pilot Trial: 1Discovery/Pre-clinical: 1Feasibility Study: 1IND-Enabling: 1Operational: 1Post-Acquisition Integration: 1N/A: 1Clinical Study Completed: 1Commercial Expansion: 1R&D: 1Phase 3/Registration: 1Late Clinical Stage: 1Phase I/IIa: 1ANDA Development / Commercial: 1In Development: 1Partnered (Virpax): 1Pre-clinical/Device Development: 1Development to Commercial: 1Phase 1-2: 1Pre-submission / Approved: 1Phase 1/2 (not specified): 1IND Approved: 1Commercial / Lifecycle Management: 1Commercial / Development: 1Clinical Stage (Pilot trial completed): 1Commercial/Research: 1Phase I/IIb: 1BLA Resubmission: 1Clinical Prototype: 1Pre-clinical through Commercial: 1Commercial (Out-licensing): 1Preclinical/Phase 1: 1Pre-clinical/Research: 1Research/Commercial: 1Commercial (Iterative Development): 1Unspecified: 1Device Commercial/Clinical Use: 1Clinical Trial (Partner-led): 1Compassionate Use / Late-stage: 1Pre-clinical/Phase 2: 1PMA: 1Clinical Development (phase unspecified): 1Phase 1/Phase 1 equivalent: 1Approved (via voluntary license): 1Commercial (CE‑approved): 1Phase I/II completed, preparing for Phase III: 1Regulatory submission: 1Launched (2024): 1Phase 1/3: 1Phase II/III: 1Phase I - Commercial: 1Development / Regulatory Filing: 1Launch (in India): 1ANDA Filed/Development: 1Phase 2 (Planned): 1IND Cleared: 1Phase 2/Phase 3: 1BLA Submission: 1Approved (China NMPA Review): 1Approved / BLA Resubmitted: 1

Drug	Company	Indication	Phase	Status
Stem Cell Therapy for Blood Diseases	GIOSTAR	Sickle Cell Anemia, Leukemia, Lymphoma, Thalassemia	Not Disclosed	Active
Stem Cell Therapy for Type 1 Diabetes	GIOSTAR	Diabetes (Type 1)	Under Development	Active
Stem Cell Therapy for Neurodegenerative Diseases	GIOSTAR	Alzheimer’s, Parkinson’s, ALS, Multiple Sclerosis	Under Development	Active
Stem Cell Therapy for Autoimmune Diseases	GIOSTAR	Lupus, Crohn's, Vasculitis, Scleroderma	Under Development	Active
KIO-301	Kiora Pharmaceuticals	Retinitis Pigmentosa (Mutation Agnostic)	Phase 1b	Active
KIO-104	Kiora Pharmaceuticals	Retinal Inflammation	Phase 2	Active
PREZIA Glaucoma Implant	PolyActiva	Glaucoma	Preclinical	Active
RareSight Pediatric Retinal Pro‑drug	PolyActiva	Rare Pediatric Retinal Diseases	Preclinical	Active
UBX1325 (foselutoclax)	Unity Biotechnology	Diabetic Macular Edema (DME)	Phase 2b	Discontinued
UBX0105	Unity Biotechnology	Moderate-to-Severe Osteoarthritis of the Knee	Phase 2	Discontinued
UBX1967	Unity Biotechnology	Diabetic Macular Edema (DME), Wet AMD	Phase 1	Discontinued
ADIFAB/ADIFAB2 Reagents	FFA Sciences	Research Tool for FFAu Measurement	Commercial	Active
FFA-Specific Probe Development	FFA Sciences	Metabolomics Profiling (Arachidonic, DHA, etc.)	Development	Active
Contract Research Services	FFA Sciences	FFAu Measurement, HTS, Binding Assays	Commercial	Active
Photosoft‑Skin	Invion	Non‑melanoma Skin Cancer	Phase 1/2	Active
Photosoft‑Solid Tumor	Invion	Hard‑to‑Treat Solid Tumors	Preclinical	Active
Photosoft‑HPV	Invion	Human Papillomavirus Lesions	Preclinical	Active
Photosoft‑Periodontal	Invion	Periodontal Disease (Human & Animal)	Preclinical	Active
Photosoft‑Eye	Invion	Non‑Cancer Eye Diseases	Preclinical	Active
CLS-AX (axitinib injectable suspension)	Clearside Biomedical	Wet Age-Related Macular Degeneration (AMD)	Phase 3 Ready	Active
XIPERE® (triamcinolone acetonide)	Clearside Biomedical	Macular Edema Associated with Uveitis	Approved	Commercial (Partnered)
CLS-AX	Clearside Biomedical	Diabetic Macular Edema (DME)	Preclinical	Research
PRF-110	PainReform	Post-operative pain following bunionectomy	Phase 3	Active/Completed (Top-line results reported)
OcuRing TD	PainReform	Extended drug release for ophthalmology surgeries	Preclinical	Platform in development
MIGS Device System	Micropoint Biotechnologies	Glaucoma	Commercial	Market approved in China
Micro-cannula System	Micropoint Biotechnologies	Vitreoretinal Surgery	Clinical	Under regulatory review
Precision Drug Delivery Device	Micropoint Biotechnologies	Retinal Diseases	Preclinical	Development
OCS-01	Oculis	Diabetic Macular Edema (DME)	Phase 3	Active
Licaminlimab (OCS-02)	Oculis	Dry Eye Disease (DED)	Phase 2/3	Active
Privosegtor (OCS-05)	Oculis	Optic Neuritis	Phase 2	Active
Tasquinimod	Active Biotech	Myelofibrosis	Phase Ib/IIa	Active
Laquinimod (eye drops)	Active Biotech	Inflammatory Eye Diseases (e.g., Uveitis)	Phase I	Completed (Safety/Biodistribution)
Naptumomab	Active Biotech	Solid Tumors (combo with durvalumab)	Phase Ib/II	Active (Partner-led)
iTrack™ Advance	Nova Eye Medical	Open‑angle glaucoma	FDA 510(k) cleared	Active
iTrack™	Nova Eye Medical	Open‑angle glaucoma (viscodilation)	CE Marked	Active
Molteno3®	Nova Eye Medical	Complex glaucoma	Commercial	Active
INM-755	InMed Pharmaceuticals	Epidermolysis Bullosa (wound care)	Phase 2	Active
INM-088	InMed Pharmaceuticals	Glaucoma	Preclinical	Active
Noregen™ (CTR-107)	RetiNova Therapeutics	Diabetic Macular Edema (DME) and Retinal Vein Occlusion (RVO)	Preclinical	Active
NGM120	NGM Biopharmaceuticals	Hyperemesis Gravidarum	Phase 2	Active
NGM831 (MK-3655)	NGM Biopharmaceuticals	Metabolic Dysfunction-Associated Steatohepatitis (MASH)	Phase 2b	Active (Merck-led)
NGM621	NGM Biopharmaceuticals	Geographic Atrophy (GA)	Phase 2	Active (Merck-led)
NGM438	NGM Biopharmaceuticals	Genetic Lipodystrophy	Preclinical	Active
Zolbetuximab	astellas	CLDN18.2-positive Gastric/GEJ Cancer	Regulatory Review	Active
Enfortumab vedotin	astellas	Urothelial Carcinoma	Phase 3	Active (Combination Trials)
AT845 (FORCE)	astellas	Late-Onset Pompe Disease	Phase 1/2	Active
ASP2138	astellas	Solid Tumors	Phase 1	Active
Gavocabtagene autoleucel	astellas	Autoimmune Diseases	Phase 1/2	Active
KESONOTIDE™	Filamon	Broad chronic inflammatory diseases	Preclinical	Active
BETA‑TT8	Filamon	Cancer, cardiovascular disease, neuroinflammatory eye conditions	Preclinical	Active